MariMed Moves Toward Federal Cannabis Compliance As DEA Registration Process Begins Ahead Of Schedule III Shift

Vertically integrated multi-state cannabis operator MariMed Inc. (CSE: MRMD) (OTCQB: MRMD) is looking to benefit from one of the biggest changes in U.S. cannabis regulation in decades.

What Happened

The company said on Thursday that it has submitted applications to the U.S. Drug Enforcement Agency (DEA) to register certain state-licensed medical cannabis operations.

Why It Matters

In order to receive the protections provided by the federal rescheduling of medical marijuana to Schedule III under the Controlled Substances Act (CSA), the company is required to register its medical cannabis licenses with the DEA.

The DEA hearing starts on Monday, June 29, 2026. It is expected to run through July 15.

“DEA registration of certain of our medical businesses marks an important step forward for MariMed as we move the Company toward becoming a federally legal business,” MariMed CEO Jon Levine said.

MariMed operates in multiple U.S. states and it focuses on medical cannabis. If the company’s medical operations qualify under Schedule III, that would make normal business expenses deductible, lower the federal tax burden, improve free cash flow and result in an uptick in earnings without selling more cannabis.

In the first quarter of fiscal 2026, MariMed reported revenue of $39.5 million, representing an increase from $37.9 million in the corresponding quarter of fiscal 2025. Adjusted EBITDA came in at $3.6 million from $2.5 million adjusted EBITDA gain in the prior year’s period. The company improved its adjusted EBITDA margin to 9% from 7%. It has also narrowed its net loss to $3.8 million from $5.5 million.

MRMD Price Action

MariMed’s shares traded 4.29% higher at $0.073 per share at the time of writing on Friday.